Who Owns Celebrex?

Celebrex is manufactured and distributed under Pfizer's corporate ESG framework. Pfizer's sustainability and ethics practices cover environmental targets, clinical research standards, and patient safety protocols.

Environmental Targets: Pfizer has committed to achieving net-zero greenhouse gas emissions across its operations by 2040. The company was the first in the pharmaceutical sector to have its climate target validated by the Science Based Target initiative. Pfizer exceeded its third-generation GHG reduction goal, achieving a 33% reduction from its 2012 baseline.

Clinical Research Ethics: Pfizer conducts clinical trials under FDA regulations and international standards including ICH-GCP guidelines. The company reports trial results publicly through ClinicalTrials.gov. Celebrex has been studied in long-term cardiovascular safety trials including the PRECISION trial, which compared Celebrex to naproxen and ibuprofen in patients with arthritis at high cardiovascular risk.

Patient Safety: Pfizer maintains pharmacovigilance systems for monitoring adverse events. Celebrex carries a boxed warning for cardiovascular and gastrointestinal risks, as required by the FDA for all NSAIDs. The drug's prescribing information includes contraindications for patients with known hypersensitivity to celecoxib, sulfonamides, or other NSAIDs.

Drug Pricing and Access: Pfizer offers patient assistance programs for eligible individuals who cannot afford their medications. The company also participates in drug donation programs in developing countries. Celebrex is available as a generic since the 2013 patent expiration, which has reduced costs for patients.

Cardiovascular Safety Concerns (2004-2005): After Merck withdrew Vioxx (rofecoxib) from the market in September 2004 due to increased cardiovascular risk, the FDA conducted extensive safety reviews of all COX-2 inhibitors, including Celebrex. The APC trial, sponsored by the National Cancer Institute, found that patients taking 400 mg of Celebrex twice daily had a 3.4-fold increased risk of cardiovascular events compared to placebo. Celebrex was not withdrawn, but the FDA required a boxed warning.

FDA Boxed Warning (2005): The FDA required Pfizer to add a boxed warning to Celebrex's label regarding cardiovascular and gastrointestinal risks. The agency also required Pfizer to conduct the PRECISION trial, a long-term cardiovascular safety study comparing Celebrex to naproxen and ibuprofen in arthritis patients at high cardiovascular risk. The PRECISION trial results, published in 2016 in the New England Journal of Medicine, found that Celebrex was non-inferior to naproxen and ibuprofen for cardiovascular safety.

Prescription Decline: Following the Vioxx withdrawal and FDA regulatory actions, Celebrex prescriptions declined significantly from peak levels. Many healthcare providers switched patients to traditional NSAIDs or alternative pain management approaches. The medication's market share decreased substantially in the years following 2004.

Litigation: Pfizer faced numerous lawsuits related to Celebrex's cardiovascular safety. Plaintiffs claimed that Pfizer failed to adequately warn patients and healthcare providers about cardiovascular risks. Pfizer resolved many of these cases through settlements. The exact financial details of most settlements were not publicly disclosed.

BYU Patent Dispute (2006-2012): Brigham Young University sued Pfizer in 2006, claiming breach of contract over royalty payments related to the COX-2 research collaboration between BYU and Monsanto. The case was settled in April 2012, with Pfizer agreeing to pay $450 million to BYU.

University of Rochester Patent Case (2004): The University of Rochester sued Searle (later Pfizer) over a patent covering methods of inhibiting COX-2. The U.S. Court of Appeals for the Federal Circuit ruled in favor of Searle in 2004, holding that the university's patent was invalid because it did not describe a specific compound that could inhibit COX-2.

Current Status: Celebrex remains on the market with a boxed warning and restricted usage guidelines. The drug is prescribed with caution for patients with existing cardiovascular risk factors. Generic celecoxib has been available since the 2013 U.S. patent expiration.